Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative bioavailability and intra-subject variability study of Risperdal Consta 12.5 mg formulations in healthy volunteers
NL-OMON44101Active, not recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of risperidone in schizophrenia (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: AUC0-t, AUC0-infinite and 6 more. Started Apr 2016; status: active, not recruiting.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NL-OMON44101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44101.